December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma
Nov 12, 2024, 17:56

Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a recent article by Amrita Krishnan on X:

SWOG Cancer Research Network S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (mmMRD) to direct Therapy Duration (DRAMMATIC) by Dr. Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski.

 Multiple Myeloma

Title: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapying Patients with Multiple Myeloma (mm) Using Minimal Residual Disease To direct Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski

 Multiple Myeloma

More posts featuring Mike Thompson.